RGS2: Regulator of G Protein Signaling 2
A key modulator of GPCR signaling with roles in cardiovascular, neurological, and immune function
Gene Information Card
| Symbol | RGS2 |
|---|---|
| Full Name | Regulator of G Protein Signaling 2 |
| Gene Type | Protein coding |
| Chromosomal Location | 1q31.2 |
| NCBI Gene ID | 5997 ncbi.nlm.nih.gov/gene/5997 |
| Ensembl ID | ENSG00000116741 |
| UniProt ID | P41220 |
| OMIM ID | 600861 |
| HGNC ID | 9998 |
| Aliases | G0S8, RGS2A, RGS2B |
Description
RGS2 (Regulator of G Protein Signaling 2) encodes a member of the regulator of G protein signaling (RGS) family. This protein functions as a GTPase-activating protein (GAP) for G alpha subunits, thereby negatively regulating G protein-coupled receptor (GPCR) signaling. RGS2 is expressed in multiple tissues and plays critical roles in blood pressure regulation, neuronal excitability, and immune responses. Mutations and altered expression of RGS2 are associated with hypertension, anxiety disorders, and certain cancers.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Hypertension | Loss of RGS2 function impairs negative regulation of Gq/11 signaling, leading to enhanced vasoconstriction and elevated blood pressure | ClinVar, OMIM #600861 |
| Anxiety disorders | Reduced RGS2 expression in the amygdala disrupts GPCR signaling balance, contributing to heightened anxiety-like behavior | OMIM #600861, NCBI Gene |
| Prostate cancer | RGS2 downregulation correlates with increased GPCR-mediated proliferation and metastasis | COSMIC, NCBI Gene |
| Cardiovascular disease | RGS2 deficiency promotes cardiac hypertrophy and fibrosis via unchecked Gq signaling | OMIM, NCBI Gene |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | 12.5 | Medium |
| Heart | 8.3 | Low |
| Lung | 15.1 | Medium |
| Liver | 6.2 | Low |
| Kidney | 10.4 | Medium |
| Spleen | 18.7 | Medium |
| Testis | 22.0 | High |
| Prostate | 14.6 | Medium |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HEK293 | 11.2 | Embryonic kidney cells |
| HeLa | 9.8 | Cervical cancer cells |
| A549 | 7.5 | Lung carcinoma cells |
| MCF7 | 13.0 | Breast cancer cells |
| PC3 | 16.4 | Prostate cancer cells |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.157C>T (p.Arg53Cys) | Missense | Rare | Reduced GAP activity; associated with hypertension |
| c.418G>A (p.Gly140Arg) | Missense | Rare | Impaired protein stability; linked to anxiety |
| c.1A>G (p.Met1Val) | Start loss | Very rare | Loss of translation initiation; likely loss of function |
| c.589_590del (p.Leu197fs) | Frameshift | Rare | Premature truncation; loss of function |
Mutation functional classification
Loss of Function (LOF)
Most reported missense and truncating mutations reduce or abolish RGS2 GAP activity, leading to prolonged G protein signaling.
Gain of Function (GOF)
No gain-of-function mutations have been clinically validated for RGS2.
Dominant Negative (DN)
Some missense variants (e.g., p.Arg53Cys) may exert dominant-negative effects by competing with wild-type RGS2 for Gα binding.
View complete mutation data：
Gene Ontology (GO)
| • GTPase activator activity | • G protein alpha-subunit binding |
| • regulation of G protein-coupled receptor signaling pathway | • negative regulation of adenylate cyclase activity |
| • intracellular signal transduction | • nervous system development |
| • blood pressure regulation |
Pathways
• GPCR downstream signaling
• G alpha (q) signaling events
• RGS protein regulation of G protein signaling
Protein Summary
RGS2 is a 211-amino acid protein containing an RGS domain that accelerates GTP hydrolysis on Gα subunits, primarily Gαq and Gαi. It is localized in the cytoplasm and nucleus, and its expression is rapidly induced by various stimuli. RGS2 modulates cardiovascular tone, neuronal excitability, and immune cell function. Structural studies show that the RGS domain forms a helical bundle that interacts with the switch regions of Gα. Post-translational modifications include phosphorylation and palmitoylation, which regulate its stability and membrane localization.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| RGS2 Knockout HEK293 Cell Line | EDJ-KQ1847 | Human | 5997 | Details Get a Quote |
| RGS20 Knockout HEK293 Cell Line | EDJ-KQ6297 | Human | 8601 | Details Get a Quote |
| RGS22 Knockout HEK293 Cell Line | EDJ-KQ8443 | Human | 26166 | Details Get a Quote |
| RGS21 Knockout HEK293 Cell Line | EDJ-KQ15057 | Human | 431704 | Details Get a Quote |
| RGS20 Knockout A-549 Cell Line | EDJ-KQ30199 | Human | 8601 | Details Get a Quote |
| RGS20 Knockout HCT 116 Cell Line | EDJ-KQ30200 | Human | 8601 | Details Get a Quote |
| RGS2 Knockout A-549 Cell Line | EDJ-KQ20396 | Human | 5997 | Details Get a Quote |
| RGS2 Knockout HCT 116 Cell Line | EDJ-KQ21706 | Human | 5997 | Details Get a Quote |
| RGS2 Knockout HeLa Cell Line | EDJ-KQ21707 | Human | 5997 | Details Get a Quote |
| RGS20 Knockout HeLa Cell Line | EDJ-KQ28887 | Human | 8601 | Details Get a Quote |
| RGS22 Knockout A-549 Cell Line | EDJ-KQ34561 | Human | 26166 | Details Get a Quote |
| RGS22 Knockout HeLa Cell Line | EDJ-KQ55889 | Human | 26166 | Details Get a Quote |
| RGS21 Knockout HeLa Cell Line | EDJ-KQ60369 | Human | 431704 | Details Get a Quote |
| RGS21 Knockout A-549 Cell Line | EDJ-KQ68837 | Human | 431704 | Details Get a Quote |
| RGS22 Knockout HCT 116 Cell Line | EDJ-KQ72830 | Human | 26166 | Details Get a Quote |
Displaying Records 1 To 15 Of 16 Records
